DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Vincristine (Vincristine) - Death - Suspected Cause - Side Effect Reports

 
 



Index of reports > Death (597)

Below is the selection of side effect reports (a.k.a. adverse event reports) related to Vincristine death. The selected reports were submitted to the FDA during the sample period of about a year.

 Reports 1 - 30 of 597   Next >>

Possible Vincristine side effects in 49 year old male

Reported by a physician from Norway on 2012-08-27

Patient: 49 year old male

Reactions: Pneumocystis Jiroveci Pneumonia, Bone Marrow Failure, Pyrexia, Lung Infiltration, Septic Shock, Infection

Adverse event resulted in: death

Drug(s) suspected as cause:
Bleomycin Sulfate
    Dosage: on day 8
    Indication: Hodgkin's Disease

Cyclophosphamide
    Dosage: for escalated cycles on day 1
    Indication: Hodgkin's Disease

Cyclophosphamide
    Dosage: for standard cycles on day 1

Doxorubicin Hydrochloride
    Dosage: for escalated cycles on day 1
    Indication: Hodgkin's Disease

Doxorubicin Hydrochloride
    Dosage: on day 1,for standard cycles

Etoposide
    Dosage: for the escalated cycles on day 1 to 3

Etoposide
    Dosage: for the escalated cycles on day 1 to 3

Etoposide
    Dosage: for the standard cycles, day 1 to 3
    Indication: Hodgkin's Disease

Prednisolone
    Dosage: on day 1 to 14 every 21 day cycle treatment for 6 cycles
    Administration route: Oral
    Indication: Hodgkin's Disease

Procarbazine Hydrochloride
    Dosage: day 1 to 7
    Administration route: Oral
    Indication: Hodgkin's Disease

Vincristine
    Dosage: on day 8
    Indication: Hodgkin's Disease



Possible Vincristine side effects in 49 year old male

Reported by a physician from Norway on 2012-08-27

Patient: 49 year old male

Reactions: Pneumocystis Jiroveci Pneumonia, Bone Marrow Failure, Septic Shock, Infection

Adverse event resulted in: death

Drug(s) suspected as cause:
Bleomycin Sulfate
    Dosage: 10000 iu, day 8 (2 escalated cycles)
    Indication: Hodgkin's Disease

Bleomycin Sulfate
    Dosage: 10000 iu, day 8 (4 standard cycles)

Cyclophosphamide
    Dosage: 650 mg/m2, day 1 (4 standard cycles)

Cyclophosphamide
    Dosage: 1250 mg/m2, day 1 (2 escalated cycles)
    Indication: Hodgkin's Disease

Doxorubicin HCL
    Dosage: 25 mg/m2, day 1 (4 standard cycles)

Doxorubicin HCL
    Dosage: 35 mg/m2, day 1 (2 escalated cycles)
    Indication: Hodgkin's Disease

Etoposide
    Dosage: 100 mg/m2, day 1-3 (4 standard cycles)

Etoposide
    Dosage: 200 mg/m2, day 1-3 (2 escalated cycles)
    Indication: Hodgkin's Disease

Prednisolone
    Dosage: 40 mg/m2, day 1-14 (4 standard cycles)
    Administration route: Oral

Prednisolone
    Dosage: 40 mg/m2, day 1-14 (2 escalated cycles)
    Administration route: Oral
    Indication: Hodgkin's Disease

Procarbazine Hydrochloride
    Dosage: 100 mg/m2, day 1-7 (2 escalated cycles)
    Administration route: Oral
    Indication: Hodgkin's Disease

Procarbazine Hydrochloride
    Dosage: 100 mg/m2, day 1-7 (4 standard cycles)
    Administration route: Oral

Vincristine
    Dosage: 1.4 mg/m2, day 8 (2 escalated cycles)
    Indication: Hodgkin's Disease

Vincristine
    Dosage: 1.4 mg/m2, day 8 (4 standard cycles)



Possible Vincristine side effects in female

Reported by a physician from Bulgaria on 2012-08-24

Patient: female, weighing 63.0 kg (138.6 pounds)

Reactions: Circulatory Collapse, Bone Marrow Failure

Adverse event resulted in: death

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: 1000 milligram
    Indication: Multiple Myeloma
    Start date: 2012-05-23
    End date: 2012-05-25

Dexamethasone
    Dosage: 40 milligram
    Start date: 2012-06-02
    End date: 2012-06-05

Dexamethasone
    Dosage: 40 milligram
    Indication: Multiple Myeloma
    Start date: 2012-05-23
    End date: 2012-05-26

Dexamethasone
    Dosage: 20 milligram
    Start date: 2012-05-16
    End date: 2012-05-19

Doxorubicin Hydrochloride
    Dosage: 80 milligram
    Indication: Multiple Myeloma
    Start date: 2012-05-26
    End date: 2012-05-26

Revlimid
    Dosage: 25 milligram
    Administration route: Oral
    Indication: Multiple Myeloma
    Start date: 2012-05-30
    End date: 2012-06-07

Vincristine
    Dosage: 2 milligram
    Indication: Multiple Myeloma
    Start date: 2012-05-26
    End date: 2012-06-02

Other drugs received by patient: Milgamma; Dopamine HCL; Nexium; Atropine; Sodium Carbonate; Lyrica; Uromithexane; Electrolyte Infusions; Sodium Bicarbonate; Probitor; Tevagrastim



Possible Vincristine side effects in female

Reported by a physician from Thailand on 2012-08-24

Patient: female, weighing 57.4 kg (126.3 pounds)

Reactions: Neutropenia

Adverse event resulted in: death, hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Indication: B-Cell Lymphoma
    Start date: 2012-03-02

Doxorubicin Hydrochloride
    Indication: B-Cell Lymphoma
    Start date: 2012-03-02

Mabthera
    Indication: B-Cell Lymphoma
    Start date: 2012-03-02

Prednisone TAB
    Indication: B-Cell Lymphoma
    Start date: 2012-03-02

Vincristine
    Indication: B-Cell Lymphoma
    Start date: 2012-03-02

Other drugs received by patient: Dexamethasone; Acetaminophen; Ondansetron; Metformin HCL; Ondansetron; Ondansetron; Atenolol; Simvastatin; Benadryl



Possible Vincristine side effects in 49 year old male

Reported by a physician from Norway on 2012-08-24

Patient: 49 year old male

Reactions: Pneumocystis Jiroveci Pneumonia, Bone Marrow Failure, Pyrexia, Lung Infiltration, Septic Shock, Infection

Adverse event resulted in: death

Drug(s) suspected as cause:
Bleomycin Sulfate
    Dosage: on day 8
    Indication: Hodgkin's Disease

Cyclophosphamide
    Dosage: for escalated cycles on day 1
    Indication: Hodgkin's Disease

Cyclophosphamide
    Dosage: for standard cycles on day 1

Doxorubicin Hydrochloride
    Dosage: on day 1,for standard cycles

Doxorubicin Hydrochloride
    Dosage: for escalated cycles on day 1
    Indication: Hodgkin's Disease

Etoposide
    Dosage: for the escalated cycles on day 1 to 3

Etoposide
    Dosage: for the escalated cycles on day 1 to 3

Etoposide
    Dosage: for the standard cycles, day 1 to 3
    Indication: Hodgkin's Disease

Prednisolone
    Dosage: on day 1 to 14 every 21 day cycle treatment for 6 cycles
    Administration route: Oral
    Indication: Hodgkin's Disease

Procarbazine Hydrochloride
    Dosage: day 1 to 7
    Administration route: Oral
    Indication: Hodgkin's Disease

Vincristine
    Dosage: on day 8
    Indication: Hodgkin's Disease



Possible Vincristine side effects in 17 year old male

Reported by a physician from Poland on 2012-08-23

Patient: 17 year old male

Reactions: Rhabdomyolysis, Disseminated Intravascular Coagulation, Pancytopenia, Pyrexia, Renal Failure, Neutropenia, Clostridial Infection, Septic Shock

Adverse event resulted in: death, hospitalization

Drug(s) suspected as cause:
Cefepime

Doxorubicin Hydrochloride
    Indication: Ewing's Sarcoma

Etoposide
    Indication: Ewing's Sarcoma Metastatic

Ifosfamide
    Indication: Ewing's Sarcoma Metastatic

Meropenem

Metronidazole

Netromycin

Vancocin Hydrochloride

Vincristine
    Indication: Ewing's Sarcoma Metastatic

Other drugs received by patient: Fluconazole; Caspofungin Acetate



Possible Vincristine side effects in 49 year old male

Reported by a physician from Norway on 2012-08-23

Patient: 49 year old male

Reactions: Pneumocystis Jiroveci Pneumonia, Bone Marrow Failure, Pyrexia, Septic Shock, Lung Infiltration

Adverse event resulted in: death

Drug(s) suspected as cause:
Bleomycin Baxter 15 000 IE Lyofilisat TIL Injeksjonsv?ske / Infusjonsv?s

Cyclophosphamide

Cyclophosphamide

Doxorubicin Hydrochloride

Doxorubicin Hydrochloride

Etoposide

Etoposide

Prednisolone
    Administration route: Oral

Procarbazine Hydrochloride
    Administration route: Oral

Vincristine



Possible Vincristine side effects in 51 year old male

Reported by a physician from Japan on 2012-08-22

Patient: 51 year old male, weighing 57.7 kg (126.9 pounds)

Reactions: Hypophosphataemia, Tumour Lysis Syndrome, Gastrointestinal Haemorrhage, Metabolic Acidosis, Hyperphosphataemia, Disseminated Intravascular Coagulation

Adverse event resulted in: death

Drug(s) suspected as cause:
Allopurinol
    Dosage: 300 mg, unk

Allopurinol
    Dosage: 200 mg, unk
    Indication: Tumour Lysis Syndrome

Cyclophosphamide
    Dosage: 1200 mg, unk
    Indication: Lymphoma

Doxorubicin HCL
    Dosage: 80 mg, unk
    Indication: Lymphoma

Methylprednisolone
    Dosage: 250 mg/day
    Indication: Lymphoma

Methylprednisolone
    Dosage: 60 mg/day

Sodium Bicarbonate
    Indication: Metabolic Acidosis

Vincristine
    Dosage: 2 mg, unk
    Indication: Lymphoma



Possible Vincristine side effects in male

Reported by a physician from United States on 2012-08-22

Patient: male

Reactions: Rectal Haemorrhage, Constipation, Cardiac Disorder, Hospitalisation, Granulocytopenia, Inappropriate Antidiuretic Hormone Secretion, Thrombocytopenia, Cardiac Failure Congestive, Pneumonia, Anaemia, Pancytopenia, Atrial Fibrillation, Febrile Neutropenia, Syncope, Embolism, Sepsis, Dehydration, Asthenia, Mantle Cell Lymphoma Recurrent, Leukopenia, Deep Vein Thrombosis, Infection

Adverse event resulted in: death, hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: on day 1
    Indication: Mantle Cell Lymphoma

Cyclophosphamide
    Dosage: on day 1
    Indication: Diffuse Large B-Cell Lymphoma

Doxorubicin HCL
    Dosage: on day 1
    Indication: Diffuse Large B-Cell Lymphoma

Doxorubicin HCL
    Dosage: on day 1
    Indication: Mantle Cell Lymphoma

Leukine
    Dosage: on day 9-15; 250 mcg/m2/day
    Indication: Mantle Cell Lymphoma

Leukine
    Dosage: on day 9-15; 250 mcg/m2/day
    Indication: Diffuse Large B-Cell Lymphoma

Prednisone TAB
    Dosage: on days 1-5
    Indication: Mantle Cell Lymphoma

Prednisone TAB
    Dosage: on days 1-5
    Indication: Diffuse Large B-Cell Lymphoma

Rituximab
    Dosage: on day 15; as infusion
    Indication: Diffuse Large B-Cell Lymphoma

Rituximab
    Dosage: on day 15; as infusion
    Indication: Mantle Cell Lymphoma

Vincristine
    Dosage: on day 1 (maximum dose: 2mg)
    Indication: Diffuse Large B-Cell Lymphoma

Vincristine
    Dosage: on day 1 (maximum dose: 2mg)
    Indication: Mantle Cell Lymphoma



Possible Vincristine side effects in male

Reported by a physician from United States on 2012-08-22

Patient: male, weighing 55.2 kg (121.4 pounds)

Reactions: Unresponsive To Stimuli, Moaning, Neutropenia, Septic Shock, Cardiac Arrest

Adverse event resulted in: death, hospitalization

Drug(s) suspected as cause:
Mercaptopurine
    Start date: 2009-08-21

Methotrexate Sodium

Prednisone

Vincristine
    End date: 2012-08-10



Possible Vincristine side effects in male

Reported by a consumer/non-health professional from Germany on 2012-08-21

Patient: male, weighing 86.0 kg (189.2 pounds)

Reactions: Pneumonia, Pulmonary Embolism, Cytomegalovirus Infection, Pulmonary Infarction, Lymphoma, Staphylococcal Sepsis

Adverse event resulted in: death, hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: 1500 mg, qd (day 1)
    Indication: T-Cell Lymphoma
    Start date: 2009-12-07
    End date: 2010-01-11

Doxorubicin HCL
    Dosage: 100 mg, qd (day 1)
    Indication: T-Cell Lymphoma
    Start date: 2009-12-07
    End date: 2010-01-11

Filgrastim
    Dosage: 48 unk, qd (day 1)
    Indication: T-Cell Lymphoma
    Start date: 2009-12-25
    End date: 2010-01-15

Mabcampath
    Dosage: 30 mg, day 4 and 5 of each cycle 1-3
    Indication: T-Cell Lymphoma
    Start date: 2009-12-10
    End date: 2010-01-15

Prednisone
    Dosage: 10 mg, qd (day 1-5)
    Administration route: Oral
    Indication: T-Cell Lymphoma
    Start date: 2009-11-27
    End date: 2010-01-10

Vincristine
    Dosage: 1 mg, qd (day 1)
    Indication: T-Cell Lymphoma
    Start date: 2009-11-26
    End date: 2010-01-11

Other drugs received by patient: Torsemide; Metoprolol Succinate; Heparin; Marcumar; Pantoprazole; Sulfamethoprim



Possible Vincristine side effects in 45 year old female

Reported by a physician from United States on 2012-08-21

Patient: 45 year old female

Reactions: Epstein-Barr Virus Infection, Splenic Infection Fungal, Mycosis Fungoides Refractory, Granuloma, Pneumonia Cytomegaloviral

Adverse event resulted in: death, hospitalization

Drug(s) suspected as cause:
Campath
    Dosage: unk
    Indication: Mycosis Fungoides
    Start date: 2006-06-01

Cisplatin
    Dosage: unk
    Indication: Mycosis Fungoides

Cyclophosphamide
    Dosage: unk
    Indication: Mycosis Fungoides
    Start date: 2006-01-01

Daunorubicin HCL
    Dosage: unk
    Indication: Mycosis Fungoides
    Start date: 2006-01-01

Dexamethasone
    Dosage: unk
    Indication: Mycosis Fungoides

Etoposide
    Dosage: unk
    Indication: Mycosis Fungoides

Fludara
    Dosage: 2 cycles
    Indication: Mycosis Fungoides

Ifosfamide
    Dosage: unk
    Indication: Mycosis Fungoides

Prednisone
    Dosage: unk
    Indication: Mycosis Fungoides
    Start date: 2006-01-01

Vincristine
    Dosage: unk
    Indication: Mycosis Fungoides
    Start date: 2006-01-01



Possible Vincristine side effects in 77 year old male

Reported by a health professional (non-physician/pharmacist) from China on 2012-08-21

Patient: 77 year old male

Reactions: Adverse Drug Reaction, Diffuse Large B-Cell Lymphoma

Adverse event resulted in: death

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: on day 1
    Indication: Diffuse Large B-Cell Lymphoma

Dexamethasone
    Dosage: in cycle 1
    Indication: Diffuse Large B-Cell Lymphoma

Doxorubicin Hydrochloride
    Dosage: on day 1
    Indication: Diffuse Large B-Cell Lymphoma

Methotrexate
    Dosage: in cycle 1
    Indication: Diffuse Large B-Cell Lymphoma

Prednisone
    Dosage: on days 1 to 5
    Indication: Diffuse Large B-Cell Lymphoma

Vincristine
    Dosage: on day 1
    Indication: Diffuse Large B-Cell Lymphoma



Possible Vincristine side effects in male

Reported by a physician from United States on 2012-08-21

Patient: male, weighing 115.7 kg (254.5 pounds)

Reactions: Gastrointestinal Haemorrhage, Cholecystitis Acute, T-Cell Lymphoma, Disseminated Intravascular Coagulation, Pancytopenia, Atrial Fibrillation, Multi-Organ Failure, Sepsis, Acute Respiratory Distress Syndrome

Adverse event resulted in: death, hospitalization

Drug(s) suspected as cause:
Adriamycin PFS
    Indication: T-Cell Lymphoma
    Start date: 2006-09-10

Cyclophosphamide
    Indication: T-Cell Lymphoma
    Start date: 2006-01-01

Prednisone TAB
    Indication: T-Cell Lymphoma
    Start date: 2006-01-01

Remicade
    Dosage: 3 dose induction followed by maint. q 8 weeks, 300 mg on 29-jun-2006, total 27 infusions
    Indication: Rheumatoid Arthritis
    Start date: 2001-10-01
    End date: 2006-06-29

Vincristine
    Indication: T-Cell Lymphoma
    Start date: 2006-09-10

Other drugs received by patient: Azulfadine; Lisinopril



Possible Vincristine side effects in 51 year old male

Reported by a physician from Japan on 2012-08-20

Patient: 51 year old male

Reactions: Hypophosphataemia, Metabolic Acidosis, Tumour Lysis Syndrome, Gastrointestinal Haemorrhage, Hyperphosphataemia, Disseminated Intravascular Coagulation

Adverse event resulted in: death

Drug(s) suspected as cause:
Allopurinol
    Dosage: unk

Cyclophosphamide
    Dosage: 1200 mg, unk
    Indication: Lymphoma

Doxorubicin
    Dosage: 80 mg, unk
    Indication: Lymphoma

Methylprednisolone
    Dosage: 60 mg/day

Methylprednisolone
    Dosage: 250 mg/day
    Indication: Lymphoma

Sodium Bicarbonate
    Indication: Metabolic Acidosis

Vincristine
    Dosage: 2 mg, unk
    Indication: Lymphoma



Possible Vincristine side effects in

Reported by a physician from United States on 2012-08-20

Patient:

Reactions: Multi-Organ Failure, Sepsis, Cerebral Ischaemia

Adverse event resulted in: death, life threatening event, hospitalization

Drug(s) suspected as cause:
Dexamethasone
    Indication: Acute Lymphocytic Leukaemia

Doxorubicin Hydrochloride
    Indication: Acute Lymphocytic Leukaemia

PEG-Asparaginase
    Indication: Acute Lymphocytic Leukaemia

Velcade
    Dosage: 1.3 mg/m2, cyclic
    Indication: Acute Lymphocytic Leukaemia

Vincristine
    Indication: Acute Lymphocytic Leukaemia



Possible Vincristine side effects in

Reported by a physician from United States on 2012-08-20

Patient:

Reactions: Multi-Organ Failure, Off Label Use, Sepsis, Cerebral Ischaemia

Adverse event resulted in: death

Drug(s) suspected as cause:
Asparaginase
    Dosage: 2500 units/m2/dose as 4 weekly doses
    Indication: Acute Lymphocytic Leukaemia

Bortezomib
    Dosage: 1.3 mg/sq.m/dose on days 1, 4, 8 and 11 combined with vxld
    Indication: Acute Lymphocytic Leukaemia

Cytarabine
    Dosage: on day 1 for all patients and on days 8, 15, 22 for cns invlovment
    Indication: Acute Lymphocytic Leukaemia

Dexamethasone
    Dosage: 10 mg/m2/day divided in to 2 doses for 14 consecutive days
    Administration route: Oral
    Indication: Acute Lymphocytic Leukaemia

Doxorubicin Hydrochloride
    Dosage: on day 1 over 15-30 minutes
    Indication: Acute Lymphocytic Leukaemia

Hydrocortisone
    Dosage: on days 8, 15 and 22
    Indication: Acute Lymphocytic Leukaemia

Methotrexate
    Dosage: 1 dose on day 15 for no cns involvement and on days 8, 15, 22 for cns involvement
    Indication: Acute Lymphocytic Leukaemia

Vincristine
    Dosage: 1.5 mg/m2/dose, max. 2 mg, by push on days 1, 8, 15 and 22
    Indication: Acute Lymphocytic Leukaemia



Possible Vincristine side effects in

Reported by a physician from United States on 2012-08-20

Patient:

Reactions: Multi-Organ Failure, Sepsis, Hypoxia, Pleural Effusion

Adverse event resulted in: death, life threatening event

Drug(s) suspected as cause:
Dexamethasone
    Indication: Acute Lymphocytic Leukaemia

Doxorubicin Hydrochloride
    Indication: Acute Lymphocytic Leukaemia

PEG-Asparaginase
    Indication: Acute Lymphocytic Leukaemia

Velcade
    Dosage: 1.3 mg/m2, cyclic
    Indication: Acute Lymphocytic Leukaemia

Vincristine
    Indication: Acute Lymphocytic Leukaemia



Possible Vincristine side effects in female

Reported by a physician from United States on 2012-08-20

Patient: female, weighing 70.8 kg (155.8 pounds)

Reactions: Abdominal Pain, Hyperpyrexia, Anaphylactic Reaction, Chills, Pain, Hepatic Failure, Transaminases Increased, Splenic Infarction, Loss of Consciousness, Aortic Thrombosis, Off Label Use, Malaise, C-Reactive Protein Increased, Myositis, Dyspnoea, Hypotension, Arrhythmia, Lung Consolidation, Hypophosphataemia, Zygomycosis, Bacteraemia, Ventricular Tachycardia, Hyperammonaemia, Neutropenia, Hepatic Infarction, Shock, Infusion Related Reaction

Adverse event resulted in: death, life threatening event

Drug(s) suspected as cause:
Cytarabine
    Dosage: day 1,8, 15 and 22
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2007-10-23

Decadron Phosphate
    Dosage: day 1
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2007-10-23

Doxil
    Dosage: day 1
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2007-10-23
    End date: 2007-10-23

Methotrexate
    Dosage: day 1
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2005-01-01
    End date: 2007-01-01

PEG-Asparaginase
    Dosage: day 2, 8, 15 and 22
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2007-10-25
    End date: 2007-10-25

Velcade
    Dosage: day 1, 4, 8 and 11
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2007-10-23
    End date: 2007-10-23

Vincristine
    Dosage: day 1,8, 15 and 22
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2007-10-23
    End date: 2007-10-23



Possible Vincristine side effects in

Reported by a physician from United States on 2012-08-20

Patient:

Reactions: Multi-Organ Failure, Sepsis, Hypoxia

Adverse event resulted in: death, life threatening event

Drug(s) suspected as cause:
Dexamethasone
    Indication: Acute Lymphocytic Leukaemia

Doxorubicin Hydrochloride
    Indication: Acute Lymphocytic Leukaemia

PEG-Asparaginase
    Indication: Acute Lymphocytic Leukaemia

Velcade
    Dosage: 1.3 mg/m2, cyclic
    Indication: Acute Lymphocytic Leukaemia

Vincristine
    Indication: Acute Lymphocytic Leukaemia



Possible Vincristine side effects in

Reported by a health professional (non-physician/pharmacist) from Japan on 2012-08-20

Patient:

Reactions: Death, Lymphoma, Diffuse Large B-Cell Lymphoma

Adverse event resulted in: death

Drug(s) suspected as cause:
Cyclophosphamide
    Indication: Diffuse Large B-Cell Lymphoma

Doxorubicin Hydrochloride
    Indication: Diffuse Large B-Cell Lymphoma

Prednisolone
    Indication: Diffuse Large B-Cell Lymphoma

Rituximab
    Indication: Diffuse Large B-Cell Lymphoma

Vincristine
    Indication: Diffuse Large B-Cell Lymphoma



Possible Vincristine side effects in 68 year old male

Reported by a health professional (non-physician/pharmacist) from Spain on 2012-08-17

Patient: 68 year old male

Reactions: Hepatitis B

Adverse event resulted in: death

Drug(s) suspected as cause:
Cyclophosphamide
    Indication: Splenic Marginal Zone Lymphoma

Doxorubicin Hydrochloride
    Indication: Splenic Marginal Zone Lymphoma

Prednisone TAB
    Indication: Immunosuppression

Rituxan
    Indication: Splenic Marginal Zone Lymphoma

Vincristine
    Indication: Splenic Marginal Zone Lymphoma



Possible Vincristine side effects in

Reported by a physician from United States on 2012-08-17

Patient:

Reactions: Off Label Use, Hypoxia, Pleural Effusion, Bacterial Sepsis

Adverse event resulted in: death

Drug(s) suspected as cause:
Asparaginase
    Dosage: (pegylated) 2500 units/ m2/ dose as 4 weekly doses
    Indication: Acute Lymphocytic Leukaemia

Bortezomib
    Dosage: on days 1, 4, 8 and 11
    Indication: Acute Lymphocytic Leukaemia

Cytarabine
    Dosage: on day 1 and as cns involvement on days 8, 15 and 22
    Indication: Acute Lymphocytic Leukaemia

Dexamethasone
    Dosage: divided into 2 doses for 14 consecutive days
    Administration route: Oral
    Indication: Acute Lymphocytic Leukaemia

Doxorubicin Hydrochloride
    Dosage: over 15-30 minutes on day 1
    Indication: Acute Lymphocytic Leukaemia

Hydrocortisone
    Dosage: on days 8, 15 and 22
    Indication: Acute Lymphocytic Leukaemia

Methotrexate
    Dosage: on day 15 and triple therapy on days 8, 15 and 22
    Indication: Acute Lymphocytic Leukaemia

Vincristine
    Dosage: by push day 1, 8, 15 and 22
    Indication: Acute Lymphocytic Leukaemia



Possible Vincristine side effects in

Reported by a physician from United States on 2012-08-16

Patient:

Reactions: B-Cell Lymphoma, Burkitt's Lymphoma, Disease Progression

Adverse event resulted in: death

Drug(s) suspected as cause:
Bortezomib
    Dosage: on day 1 and repeated on day 8 of each cycle
    Indication: B-Cell Lymphoma

Cyclophosphamide
    Dosage: on day 1
    Indication: B-Cell Lymphoma

Doxorubicin HCL
    Dosage: administered over 3 to 5 minutes
    Indication: B-Cell Lymphoma

Doxorubicin HCL
    Dosage: administered over 3 to 5 minutes

Prednisone TAB
    Dosage: day 1-5
    Administration route: Oral
    Indication: B-Cell Lymphoma

Rituximab
    Dosage: on day 1
    Indication: B-Cell Lymphoma

Vincristine
    Dosage: day 1-5, capped 1.5 mg
    Administration route: Oral
    Indication: B-Cell Lymphoma

Other drugs received by patient: Diphenhydramine Hydrochloride; Acetaminophen; Prednisone TAB; Ondansetron



Possible Vincristine side effects in

Reported by a physician from United States on 2012-08-16

Patient:

Reactions: Gastrointestinal Perforation, Thrombosis, Left Ventricular Dysfunction, Sudden Death, Blood Disorder, Hypertension

Adverse event resulted in: death

Drug(s) suspected as cause:
Adriamycin PFS
    Dosage: every 21 days for a maximum of 8 cycles
    Indication: Diffuse Large B-Cell Lymphoma

Bevacizumab
    Dosage: on day 1, every 21 days for a maximum of 8 cycles
    Indication: Diffuse Large B-Cell Lymphoma

Cyclophosphamide
    Dosage: every 21 days for a maximum of 8 cycles
    Indication: Diffuse Large B-Cell Lymphoma

Doxorubicin Hydrochloride
    Dosage: every 21 days for a maximum of 8 cycles
    Indication: Diffuse Large B-Cell Lymphoma

Prednisone TAB
    Dosage: every 21 days for a maximum of 8 cycles
    Indication: Diffuse Large B-Cell Lymphoma

Rituximab
    Dosage: every 21 days for a maximum of 8 cycles
    Indication: Diffuse Large B-Cell Lymphoma

Vincristine
    Dosage: every 21 days for a maximum of 8 cycles
    Indication: Diffuse Large B-Cell Lymphoma



Possible Vincristine side effects in 9 year old female

Reported by a physician from Germany on 2012-08-16

Patient: 9 year old female, weighing 28.0 kg (61.6 pounds)

Reactions: Pulmonary Hypertension, Cardiopulmonary Failure, Pulmonary Embolism

Adverse event resulted in: death

Drug(s) suspected as cause:
Dactinomycin
    Indication: Rhabdomyosarcoma
    Start date: 2012-01-15

Ifosfamide
    Indication: Rhabdomyosarcoma
    Start date: 2012-01-15

Toluidinblau
    Start date: 2012-01-14
    End date: 2012-01-15

Vincristine
    Indication: Rhabdomyosarcoma
    Start date: 2012-01-15

Other drugs received by patient: Acetaminophen; Metamizol; Cotrim; Mesna; Hydromorphon; Granisetron; Heparin Sodium; Fortum 1,0 G; Metoclopramide; Dimenhydrinate



Possible Vincristine side effects in

Reported by a physician from United States on 2012-08-15

Patient:

Reactions: Death

Adverse event resulted in: death

Drug(s) suspected as cause:
Cytarabine
    Dosage: unk
    Indication: Acute Lymphocytic Leukaemia

Dexamethasone
    Dosage: 10 mg/m2, cyclic
    Administration route: Oral
    Indication: Acute Lymphocytic Leukaemia

Doxorubicin Hydrochloride
    Dosage: 60 mg/m2, cyclic
    Indication: Acute Lymphocytic Leukaemia

Hydrocortisone
    Indication: Acute Lymphocytic Leukaemia

Methotrexate
    Dosage: unk, cyclic
    Indication: Acute Lymphocytic Leukaemia

PEG-Asparaginase
    Dosage: unk, cyclic
    Indication: Acute Lymphocytic Leukaemia

Velcade
    Dosage: 1.3 mg/m2, cyclic
    Indication: Acute Lymphocytic Leukaemia

Vincristine
    Dosage: 1.5 mg/m2, cyclic
    Indication: Acute Lymphocytic Leukaemia



Possible Vincristine side effects in

Reported by a physician from United States on 2012-08-15

Patient:

Reactions: Death

Adverse event resulted in: death

Drug(s) suspected as cause:
Cytarabine
    Dosage: unk
    Indication: Acute Lymphocytic Leukaemia

Decadron
    Dosage: 10 mg/m2, cyclic
    Administration route: Oral
    Indication: Acute Lymphocytic Leukaemia

Doxorubicin Hydrochloride
    Dosage: 60 mg/m2, cyclic
    Indication: Acute Lymphocytic Leukaemia

Hydrocortisone
    Indication: Acute Lymphocytic Leukaemia

Methotrexate
    Dosage: unk, cyclic
    Indication: Acute Lymphocytic Leukaemia

Oncaspar
    Dosage: unk, cyclic
    Indication: Acute Lymphocytic Leukaemia

Velcade
    Dosage: 1.3 mg/m2, cyclic
    Indication: Acute Lymphocytic Leukaemia

Vincristine
    Dosage: 1.5 mg/m2, cyclic
    Indication: Acute Lymphocytic Leukaemia



Possible Vincristine side effects in

Reported by a physician from United States on 2012-08-15

Patient:

Reactions: Death

Adverse event resulted in: death

Drug(s) suspected as cause:
Cytarabine
    Dosage: unk
    Indication: Acute Lymphocytic Leukaemia

Dexamethasone
    Dosage: 10 mg/m2, cyclic
    Administration route: Oral
    Indication: Acute Lymphocytic Leukaemia

Doxorubicin Hydrochloride
    Dosage: 60 mg/m2, cyclic
    Indication: Acute Lymphocytic Leukaemia

Hydrocortisone
    Indication: Acute Lymphocytic Leukaemia

Methotrexate
    Dosage: unk, cyclic
    Indication: Acute Lymphocytic Leukaemia

PEG-Asparaginase
    Dosage: unk, cyclic
    Indication: Acute Lymphocytic Leukaemia

Velcade
    Dosage: 1.3 mg/m2, cyclic
    Indication: Acute Lymphocytic Leukaemia

Vincristine
    Dosage: 1.5 mg/m2, cyclic
    Indication: Acute Lymphocytic Leukaemia



Possible Vincristine side effects in

Reported by a physician from United States on 2012-08-15

Patient:

Reactions: Death

Adverse event resulted in: death

Drug(s) suspected as cause:
Cytarabine
    Dosage: unk
    Indication: Acute Lymphocytic Leukaemia

Decadron
    Dosage: 10 mg/m2, cyclic
    Administration route: Oral
    Indication: Acute Lymphocytic Leukaemia

Doxorubicin Hydrochloride
    Dosage: 60 mg/m2, cyclic
    Indication: Acute Lymphocytic Leukaemia

Hydrocortisone
    Indication: Acute Lymphocytic Leukaemia

Methotrexate
    Dosage: unk, cyclic
    Indication: Acute Lymphocytic Leukaemia

Oncaspar
    Dosage: unk, cyclic
    Indication: Acute Lymphocytic Leukaemia

Velcade
    Dosage: 1.3 mg/m2, cyclic
    Indication: Acute Lymphocytic Leukaemia

Vincristine
    Dosage: 1.5 mg/m2, cyclic
    Indication: Acute Lymphocytic Leukaemia



 Page 1   Next >>

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017